Key result
Extended biventricular assist device support for 12 months in a patient with giant cell myocarditis resulted in extensive fibrosis but no evidence of active disease in the explanted heart.
Case Report (n=1)
Extended BiVAD support without immunosuppression may allow for the resolution of active giant cell myocarditis prior to heart transplantation.
Answers are grounded in this paper and cite their sources.
Supports hypothesis of BiVAD as immunosuppression-free bridge in giant cell myocarditis; leaves open need for prospective validation before practice change.
Lower recurrence rates and improved long-term outcomes are the goal of treatment for giant cell myocarditis (GCM). We describe a case of GCM in an Asian woman who presented with new onset palpitations and syncope. She initially had normal systolic function by echocardiography with magnetic resonance imaging evidence of infiltrative cardiomyopathy. She underwent implantation of a biventricular assist device (BiVAD) because of rapidly deteriorating hemodynamic status. Giant cell myocarditis was diagnosed at that time by surgical biopsy. She was not treated with immunosuppressive therapy because of low likelihood of recovery and concerns for potential infection with the BiVAD in place. She received a heart transplant 12 months later and had extensive fibrosis but no evidence of active GCM in the heart explant. The role of extended BiVAD support in patients with GCM should be further investigated.
No takes yet. Share an insight, caveat, or question.
Eid et al. (2009) conducted a case report in Giant cell myocarditis (n=1). Biventricular assist device (BiVAD) implantation was evaluated on Evidence of active giant cell myocarditis in the heart explant. Extended biventricular assist device support for 12 months in a patient with giant cell myocarditis resulted in extensive fibrosis but no evidence of active disease in the explanted heart.
Synapse has enriched 10 related papers. Consider them for comparative context: